The FDA approved atezolizumab for adjuvant treatment of muscle invasive bladder cancer with ctDNA molecular residual disease after cystectomy.
← News
Medicine Breakthroughs Medicine Breakthroughs Health
May 2026 Brief | FDA Briefs | Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
Muscle Invasive Bladder Cancer Adjuvant Treatment Indication
CtDNA Molecular Residual Disease Post-Cystectomy Requirement